Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
India
/
Pharmaceuticals & Biotech
/
Ajanta Pharma
AJANTPHARM
Ajanta Pharma
Tightening Global Regulations And Supply Risks Will Drag Outlook
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 12 Analysts
Published
13 Jul 25
Updated
23 Jul 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
₹2,044.56
29.6% overvalued
intrinsic discount
23 Jul
₹2,649.30
Loading
1Y
-13.6%
7D
0.5%
Author's Valuation
₹2.0k
29.6% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
₹2.0k
29.6% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
66b
2015
2017
2019
2021
2023
2025
2027
2028
Revenue ₹65.6b
Earnings ₹13.0b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
10.75%
Pharma revenue growth rate
1.00%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
12.73%
Calculation
₹13.03b
Earnings '28
x
27.75x
PE Ratio '28
=
₹361.44b
Market Cap '28
₹361.44b
Market Cap '28
/
125.38m
No. shares '28
=
₹2.88k
Share Price '28
₹2.88k
Share Price '28
Discounted to 2025 @ 12.55% p.a.
=
₹2.02k
Fair Value '25